GlassScriptPhysician profile
Kevin A Stephens
NPI 1255414314
$5,819.30
in general payments reported to CMS, 2019-2025
24 companies · $881 in 2025
The $881 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,291 · 2020: $324 · 2021: $1,294 · 2022: $948 · 2023: $387 · 2024: $695 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,962.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $942.41 | 2019-2025 | Descovy, Yeztugo |
| Astrazeneca Pharmaceuticals LP | $901.24 | 2019-2025 | Farxiga |
| Amgen INC. | $764.24 | 2019-2025 | Repatha, Repatha, Krystexxa |
| Lilly USA, LLC | $391.50 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $383.70 | 2019-2021 | |
| Abiomed | $271.59 | 2021-2022 | |
| Esperion Therapeutics, INC. | $250.53 | 2021 | |
| Abbvie INC. | $222.76 | 2019-2022 | |
| Abbott Laboratories | $198.70 | 2022 | |
| Novo Nordisk INC | $196.54 | 2021-2022 | |
| Antares Pharma, INC. | $176.88 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Glaxosmithkline, LLC. | $165.64 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Shockwave Medical, INC | $148.38 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Inspire Medical Systems, INC. | $139.32 | 2024 | Inspire |
| Bard Peripheral Vascular, INC. | $122.51 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.52 | 2021 | |
| Tms Neurohealth Centers INC. | $118.72 | 2025 | Tms Neurohealth Centers INC. |
| Merck Sharp & Dohme LLC | $112.92 | 2022-2025 | Pifeltro, Delstrigo, Isentress |
| Teleflex LLC | $84.28 | 2025 | Barrigel |
| Viiv Healthcare Company | $39.59 | 2024-2025 | Apretude |
| Tolmar, INC. | $19.99 | 2023 | |
| Halozyme INC | $16.95 | 2023 | |
| Ironshore Pharmaceuticals INC. | $16.02 | 2024 | |
| Idorsia Pharmaceuticals US INC | $15.37 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.